Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Qiagen ( (QGEN) ).
Qiagen N.V. has announced a notification from the Netherlands Authority For the Financial Markets (AFM) regarding BlackRock, Inc.’s voting rights in the company. The notification, dated September 9, 2025, reveals BlackRock’s significant indirect holdings in Qiagen, with a capital interest of 9.92% and voting rights of 11.08%. This disclosure highlights BlackRock’s substantial influence in Qiagen, potentially impacting the company’s strategic decisions and stakeholder dynamics.
The most recent analyst rating on (QGEN) stock is a Buy with a $52.00 price target. To see the full list of analyst forecasts on Qiagen stock, see the QGEN Stock Forecast page.
More about Qiagen
Qiagen N.V. operates in the biotechnology industry, specializing in sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research. The company is known for its innovative solutions that enable customers to gain valuable insights from biological samples.
Average Trading Volume: 1,444,451
Technical Sentiment Signal: Buy
Current Market Cap: $9.81B
Find detailed analytics on QGEN stock on TipRanks’ Stock Analysis page.